[1] 李莉,朱文娟,郭妮,等. 泼尼松龙联合异甘草酸镁治疗自身免疫性肝炎患者疗效研究. 实用肝脏病杂志,2025,28(4):561-564. [2] 李晓静,黄丽,莫波,等. 影响泼尼松治疗自身免疫性肝炎患者完全应答的多因素分析. 实用肝脏病杂志,2025,28(4):565-568. [3] Sekhri R, Patel K. Looking beyond plasma cells: clinical and histopathologic characteristics of overlapping autoimmune hepatitis in nonalcoholic steatohepatitis. Arch Pathol Lab Med, 2025, 149(8):E184-E185. [4] 管海燕,张慧,张毅,等. 肝脂肪变性对泼尼松与硫唑嘌呤联合治疗的自身免疫性肝炎患者治疗应答的影响. 实用肝脏病杂志,2025,28(2):214-217. [5] Noemi R, Xinbo Z, Alberto C, et al. Antagonism of miR-148a attenuates atherosclerosis progression in APOBTGApobec-/-Ldlr+/- mice: A brief report. Biomed Pharmacother, 2022, 15(3):113419-113419. [6] 杜颖,姜志红,吴雅玲. 雷公藤多甙联合异甘草酸镁治疗儿童自身免疫性肝炎疗效及其对血清IL-17和CXCL10水平的影响. 实用肝脏病杂志,2020,23(3):348-351. [7] Li T, Pan T, Zheng N, et al. STAT3-dependent effects of polymeric immunoglobulin receptor in regulating interleukin-17 signaling and preventing autoimmune hepatitis. Engineering, 2024, 3(6):209-222. [8] 中华医学会肝病学分会. 自身免疫性肝炎诊断和治疗指南(2021). 中华肝脏病杂志,2022,30(5):482-492. [9] 王丽,杨永峰. 自身免疫性肝炎的病理特征和病理诊断标准. 中华肝脏病杂志,2025,33(7):622-627. [10] 朱家瑞,葛绍锋,叶桂云,等. 自身免疫性肝炎患者外周血NLR和nCD64指数变化及其临床意义探讨. 实用肝脏病杂志,2024,27(5):717-720. [11] Huang Z, Zhou S, Wang J, et al. MiR-148a promotes the expression of multiple alcohol dehydrogenase genes by activating an ADH4 enhancer element. Int J Biol Macromol, 2025, 330(Pt 1):148015. [12] 蒋叶舟,花霞,陈国飞,等. 自身免疫性肝炎患者血清瘦素、外周血调节性T细胞和Th17细胞水平变化. 实用肝脏病杂志,2024,27(5):713-716. [13] Siyuan T, Xia Z, Miao Z, et al. Mesenchymal stem cell-derived exosomes protect against liver fibrosis via delivering miR-148a to target KLF6/STAT3 pathway in macrophages. Stem Cell Res Ther,2022,13(1):330-330. [14] Magdy K I, I H A, Laila R, et al. A low dose of naloxone mitigates autoimmune hepatitis by regulating TLR4/NF-κB and Nrf2/HO-1 signaling pathways. Inflamm Pharmacol, 2023, 31(5):2467-2478. [15] Dan C, Ping L, Tianfeng S, et al. Long non-coding RNA HOX transcript antisense intergenic RNA depletion protects against alcoholic hepatitis through the microRNA-148a-3p/sphingosine 1-phosphate receptor 1 axis. Cell Tissue Res, 2023, 394(3):471-485. [16] Ahmad I, Hamidullah, Ashraf, et al. Determination of correlation between cytokines IL 6, IL8, IL10, IL12, IL17 and severity of hepatocellular carcinoma in patients having hepatitis C. J Pak Med Assoc, 2024, 74(12):2078-2085. [17] Shao W, Huang W, Wang Y, et al. Exosome-modified AAV genetherapy attenuates autoimmune hepatitis via enhanced regulatory T cell targeting and immune modulation. Microorganisms, 2025, 13(4):823-823. [18] Muratori L, Lohse AW, Lenzi M.Diagnosis and management of autoimmune hepatitis. BMJ,2023,380:e070201. [19] Renquan J, Jifeng T, Xuehao Z, et al. CCN1 promotes inflammation by inducing il-6 production via α6β1/pi3k/akt/nf-κb pathway in autoimmune hepatitis. Front Immunol, 2022, 1(3):810671-810671. [20] Zhao G, Qi H, Liu M,et al. Rhoifolin attenuates concanavalin a-induced autoimmune hepatitis in mice via jaks/stats mediated immune and apoptotic processes. ACS omega, 2024, 9(42):43233-43251. |